IS4551A - Freyðandi fjöleininga-skammtaform sem inniheldur prótónupumpublokkara - Google Patents

Freyðandi fjöleininga-skammtaform sem inniheldur prótónupumpublokkara

Info

Publication number
IS4551A
IS4551A IS4551A IS4551A IS4551A IS 4551 A IS4551 A IS 4551A IS 4551 A IS4551 A IS 4551A IS 4551 A IS4551 A IS 4551A IS 4551 A IS4551 A IS 4551A
Authority
IS
Iceland
Prior art keywords
annoying
dosage form
unit dosage
proton pump
form containing
Prior art date
Application number
IS4551A
Other languages
English (en)
Inventor
Johan Lundberg Per
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS4551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS4551A publication Critical patent/IS4551A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IS4551A 1996-01-08 1997-08-25 Freyðandi fjöleininga-skammtaform sem inniheldur prótónupumpublokkara IS4551A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600073A SE512835C2 (sv) 1996-01-08 1996-01-08 Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
PCT/SE1996/001738 WO1997025030A1 (en) 1996-01-08 1996-12-20 Multiple unit effervescent dosage forms comprising protonpump inhibitor

Publications (1)

Publication Number Publication Date
IS4551A true IS4551A (is) 1997-08-25

Family

ID=20400971

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4551A IS4551A (is) 1996-01-08 1997-08-25 Freyðandi fjöleininga-skammtaform sem inniheldur prótónupumpublokkara

Country Status (33)

Country Link
US (1) US6132770A (is)
EP (1) EP0814783B1 (is)
JP (1) JP4638561B2 (is)
KR (1) KR100459363B1 (is)
CN (1) CN100335043C (is)
AR (1) AR005280A1 (is)
AT (1) ATE251451T1 (is)
AU (1) AU712325B2 (is)
BR (1) BR9607367A (is)
CA (1) CA2214027C (is)
CZ (1) CZ280797A3 (is)
DE (1) DE69630286T2 (is)
DK (1) DK0814783T3 (is)
EE (1) EE9700189A (is)
ES (1) ES2208775T3 (is)
HR (1) HRP970005A2 (is)
HU (1) HUP0000976A3 (is)
ID (1) ID15819A (is)
IL (1) IL121653A (is)
IS (1) IS4551A (is)
MX (1) MX9706768A (is)
NO (1) NO319999B1 (is)
NZ (1) NZ325978A (is)
PL (1) PL322161A1 (is)
PT (1) PT814783E (is)
SE (1) SE512835C2 (is)
SI (1) SI0814783T1 (is)
SK (1) SK117197A3 (is)
TN (1) TNSN97002A1 (is)
TR (1) TR199700918T1 (is)
WO (1) WO1997025030A1 (is)
YU (1) YU70196A (is)
ZA (1) ZA9610939B (is)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
DK1037607T3 (da) * 1997-12-08 2004-06-21 Altana Pharma Ag Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
CA2320963A1 (en) * 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
EP2263660B1 (en) * 1998-05-18 2017-09-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
DE69942777D1 (de) 1998-07-28 2010-10-28 Takeda Pharmaceutical Leicht zerfallende feste Zubereitung
PL360916A1 (en) * 1999-03-29 2004-09-20 Wyeth Coating system
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
SI1341528T1 (sl) 2000-12-07 2012-05-31 Nycomed Gmbh Hitro razpadljiva tableta ki obsega kislinsko labilno aktivno sestavino
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
JP4448695B2 (ja) 2002-03-27 2010-04-14 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アルコキシピリジン−誘導体
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
SI1606261T1 (sl) 2003-03-10 2010-03-31 Nycomed Gmbh Novi postopek za pripravo roflumilasta
US20060177506A1 (en) * 2003-03-17 2006-08-10 Shigeo Yanai Release control compositions
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
JP2007507463A (ja) 2003-10-01 2007-03-29 アルタナ　ファルマ　アクチエンゲゼルシャフト 誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体
US7279488B2 (en) 2003-10-01 2007-10-09 Nycomed Gmbh Imidazopyridine-derivatives as inducible no-synthase inhibitors
CA2540083A1 (en) 2003-10-01 2005-04-07 Altana Pharma Ag Imidazopyridine-derivatives as inductible no-synthase inhibitors
BRPI0415034A (pt) 2003-10-01 2006-12-12 Altana Pharma Ag derivados de aminopiridina como inibidores de não-sintase induzìveis
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
RU2440101C2 (ru) * 2005-08-15 2012-01-20 Зольвай Фармасьютиклз Гмбх Фармацевтические композиции регулируемого высвобождения нестабильных в кислой среде лекарственных средств
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US7776831B2 (en) 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
EP1837016A3 (en) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP1834634A3 (en) * 2006-03-08 2007-10-03 Rentschler Pharma GmbH Pharmaceutical multiple-unit composition
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
AU2007278986B2 (en) * 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
EP2044932A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Mechanical protective layer for solid dosage forms
KR102193599B1 (ko) 2014-09-17 2020-12-21 스티어라이프 인디아 프라이빗 리미티드 발포성 조성물 및 이의 제조방법
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10583089B2 (en) * 2016-07-19 2020-03-10 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions
CN112574835A (zh) * 2019-09-30 2021-03-30 埃科莱布美国股份有限公司 泡腾片清洁剂及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) * 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) * 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
US4568560A (en) * 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
WO1986007348A1 (en) * 1985-06-03 1986-12-18 Hughes Aircraft Company Method for introducing dopants in optical fiber preforms
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
JP3142919B2 (ja) * 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
KR930017902A (ko) * 1992-02-14 1993-09-20 알베르투스 빌헬무스 요아네스 째스트라텐 살충제 화합물 및 그의 제조 방법
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
KR970011587B1 (ko) * 1992-07-31 1997-07-12 삼성전자 주식회사 Mac 시스템의 프레임 싱크 검출회로
ATE217188T1 (de) * 1992-08-05 2002-05-15 Faulding F H & Co Ltd Granulierte pharmazeutische zusammensetzung
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
JP3017906B2 (ja) * 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
WO1995010264A1 (en) * 1993-10-12 1995-04-20 Tokyo Tanabe Company Limited Tablet containing enteric granules
GB2285989A (en) * 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
PT1078628E (pt) * 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare

Also Published As

Publication number Publication date
SE9600073D0 (sv) 1996-01-08
DE69630286T2 (de) 2004-07-22
CZ280797A3 (cs) 1998-03-18
NO974051D0 (no) 1997-09-03
CA2214027A1 (en) 1997-07-17
HUP0000976A3 (en) 2000-12-28
NO319999B1 (no) 2005-10-10
HUP0000976A2 (hu) 2000-11-28
SE9600073L (sv) 1997-07-09
ZA9610939B (en) 1997-07-08
TR199700918T1 (xx) 1997-11-21
ATE251451T1 (de) 2003-10-15
AU1324297A (en) 1997-08-01
SI0814783T1 (en) 2004-04-30
EP0814783A1 (en) 1998-01-07
US6132770A (en) 2000-10-17
CN1183716A (zh) 1998-06-03
YU70196A (sh) 1999-07-28
CN100335043C (zh) 2007-09-05
NO974051L (no) 1997-10-15
AU712325B2 (en) 1999-11-04
DK0814783T3 (da) 2004-01-26
SE512835C2 (sv) 2000-05-22
JP4638561B2 (ja) 2011-02-23
PT814783E (pt) 2004-02-27
KR19980702830A (ko) 1998-08-05
KR100459363B1 (ko) 2005-01-17
EE9700189A (et) 1998-02-16
NZ325978A (en) 1999-02-25
ES2208775T3 (es) 2004-06-16
EP0814783B1 (en) 2003-10-08
IL121653A (en) 2001-08-08
MX9706768A (es) 1997-11-29
JPH11501951A (ja) 1999-02-16
DE69630286D1 (de) 2003-11-13
ID15819A (id) 1997-08-14
PL322161A1 (en) 1998-01-19
BR9607367A (pt) 1997-12-30
TNSN97002A1 (fr) 2005-03-15
SK117197A3 (en) 1998-05-06
AR005280A1 (es) 1999-04-28
IL121653A0 (en) 1998-02-08
WO1997025030A1 (en) 1997-07-17
CA2214027C (en) 2006-09-05
HRP970005A2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
IS4551A (is) Freyðandi fjöleininga-skammtaform sem inniheldur prótónupumpublokkara
IS4550A (is) Lyf í formi skammta til inntöku um munn sem inniheldur prótónupumpublokkara og prókínetískt efni
DE69704965D1 (de) Dosierungs-Ausgabebehälter
HUP9801626A3 (en) Pharmaceutical composition containing proton pump inhibitors
DE69705301D1 (de) Flüssiger protonenleiter
DE69706416D1 (de) Fernmeldedienstlieferung
PT804438E (pt) Benzazepinas triciclicas antagonistas da vasopressina
IS4478A (is) Tæki sem sýnir skammta
IS4548A (is) Lyf í formi skammta til inntöku um munn sem inniheldur prótónupumpublokkara og sýrueyði eða algínat
GB9809413D0 (en) Conference call
ATE321483T1 (de) Dose
EP0956018A4 (en) IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
DE69730228D1 (de) Multimedia-anrufzentrale
NL194779B (nl) Gestabiliseerd vrijdragend patiÙnttafelstelsel.
IS4546A (is) Lyf í formi skammta til inntöku um munn sem inniheldur prótónupumpublokkara og bólgueyðandi lyf án stera
DE69928777D1 (de) Dosierspender
DE69730853D1 (de) Anrufkreditverwaltungsverfahren
IS5062A (is) Lyfjablöndur sem innihalda afleiður N-súlfonýlindólíns
PL338781A1 (en) Dosage form
GB9712213D0 (en) Hydraullic boom stop
DE59701880D1 (de) Fadenliefergerät
DE59701884D1 (de) Fadenliefergerat
DE59701913D1 (de) Fadenliefergerät
DE59902337D1 (de) Fadenliefersystem
DE69725034D1 (de) Diffusionspumpe